Robert W. Baird Issues Positive Forecast for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its target price increased by equities research analysts at Robert W. Baird from $85.00 to $98.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the medical device company’s stock. Robert W. Baird’s price objective would indicate a potential upside of 27.22% from the stock’s current price.

A number of other research analysts have also recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $100.00 price objective (up from $94.00) on shares of Cooper Companies in a report on Friday. Morgan Stanley set a $76.00 price objective on shares of Cooper Companies and gave the company an “equal weight” rating in a report on Thursday, August 28th. Piper Sandler reiterated an “overweight” rating and set a $94.00 price target on shares of Cooper Companies in a research report on Friday. Wells Fargo & Company restated an “equal weight” rating and issued a $72.00 price objective on shares of Cooper Companies in a report on Thursday, November 13th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.08.

Cooper Companies Trading Up 1.4%

Shares of Cooper Companies stock opened at $77.03 on Friday. Cooper Companies has a 1-year low of $61.78 and a 1-year high of $104.47. The stock has a market cap of $15.31 billion, a P/E ratio of 37.95, a P/E/G ratio of 1.87 and a beta of 1.05. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The stock’s 50 day simple moving average is $72.01 and its 200-day simple moving average is $71.74.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.11 by $0.04. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Analysts predict that Cooper Companies will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a share buyback program on Wednesday, September 17th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In other Cooper Companies news, Director Lawrence Erik Kurzius bought 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The stock was purchased at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the purchase, the director directly owned 5,777 shares in the company, valued at $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.98% of the stock is currently owned by corporate insiders.

Institutional Trading of Cooper Companies

Several institutional investors and hedge funds have recently added to or reduced their stakes in COO. Cetera Investment Advisers boosted its stake in shares of Cooper Companies by 1.7% in the first quarter. Cetera Investment Advisers now owns 24,461 shares of the medical device company’s stock valued at $2,063,000 after buying an additional 412 shares in the last quarter. LPL Financial LLC raised its position in Cooper Companies by 4.7% during the first quarter. LPL Financial LLC now owns 148,261 shares of the medical device company’s stock worth $12,506,000 after acquiring an additional 6,657 shares during the last quarter. New Age Alpha Advisors LLC grew its holdings in Cooper Companies by 3,223.5% during the 1st quarter. New Age Alpha Advisors LLC now owns 13,593 shares of the medical device company’s stock valued at $1,147,000 after buying an additional 13,184 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Cooper Companies by 17.0% during the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock worth $399,340,000 after buying an additional 686,751 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. purchased a new position in Cooper Companies during the first quarter worth $304,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.